NCT03586726View on ClinicalTrials.gov

A Study to Investigate the Effect of Rifampicin on the PK of Multiple Doses of Balovaptin In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 24, 2018

Primary Completion Date

November 2, 2018

Study Completion Date

November 15, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

Balovaptan

"In Period 1, balovaptan was administered alone as a once daily (qd) dose on Days 1 to 10.~In Period 2, balovaptan was administered as a qd dose on Days 7 to 16."

DRUG

Rifampicin

In Period 2, 600 mg of rifampicin will be administered alone as a qd dose from Day 1 to Day 6, and as a qd dose on Days 7 to 16.

Trial Locations (1)

9728 NZ

Pra International Group B.V, Groningen

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03586726 - A Study to Investigate the Effect of Rifampicin on the PK of Multiple Doses of Balovaptin In Healthy Volunteers | Biotech Hunter | Biotech Hunter